Designs - Indwelling Urinary Catheters - UroToday
Designs - Indwelling Urinary Catheters. Catheters are semi-rigid but flexible tubes. They drain the bladder but block the urethra. The challenge is to produce a catheter that matches as closely as possible to the normal physiological and mechanical characteristics of the voiding system. This requires construction of a thin-walled, continuously ...
Complications & Adverse Events – External Urinary Catheters
An external urine collection device (EUCD) may be external and less invasive but they are not free of risks. Complications and adverse effects include skin lesion/ulceration and breakdown from pressure necrosis and moisture, urethral fistula or very rarely, gangrene of the penis. The majority of complications involve perineal/genital skin ...
The Relationship Between PSA and Total Testosterone Levels
May 9, 2022 Rates of low serum testosterone (T) and prostate cancer (PC) increase with age, both impacting the health and quality of life of older men. 1 Low T may impact men’s overall health, with increased risks of lower bone mineral density, pre-diabetes/diabetes, metabolic syndrome, and major adverse cardiovascular events. 1,2 PC is an androgen-dependent …
Novel Targets and Treatment Developments in Metastatic …
The last decade has seen a seismic shift in the treatment landscape of metastatic hormone sensitive prostate cancer (mHSPC). This includes several guideline and FDA approved doublet therapy options, triplet therapy options, and treatment with radiotherapy to the primary tumor: ADT + apalutamide 1,2. ADT + enzalutamide 3-6. ADT + abiraterone 7-9.
EAU 2024: Extended Follow-up from CheckMate 274 Including
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a game changing session on prime time for adjuvant treatment in locally advanced bladder cancer, and a presentation by Dr. Matthew Galsky discussing extended follow-up from the CheckMate 274 trial, including the first report of overall survival outcomes.
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for
ASCO GU 2024, CheckMate 214 trial, nivolumab, ipilimumab, nivolumab plus ipilimumab, renal cell carcinoma (RCC), checkpoint inhibitor combination therapy.
Enzalutamide vs. a Combination of Ra223 and Enzalutamide in ...
Introduction Radium-223 dichloride (radium-223) is a targeted alpha emitter that selectively binds to areas of increased bone turnover in bone metastases and emits high-energy alpha particles of short-range (<100 μm).
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in …
2024年10月11日 · Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. He …
ESMO 2024: UpFrontPSMA : A Randomized Phase II Study of …
ESMO 2024 results of UpFrontPSMA, a randomized phase II trial of sequential 177Lu-PSMA-617 plus docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).
ASCO GU 2024: BCG Shortage: What’s on the Horizon to Replace?
(UroToday.com) The 2024 GU ASCO annual meeting featured a session on the shortage of drugs for urothelial carcinoma and a presentation by Dr. Josh Meeks discussing what is on the horizon to replace BCG. Dr. Meeks started his presentation with a case report of a 71 year old female who presented with gross hematuria and a CT scan showing a 3 cm bladder mass.